News
Insider Insight: Oriana Papin-Zoghbi, CEO and co-founder of AOA Dx
AOA Dx was founded in 2020 with the aim of giving women access to the most innovative early detection platform in their fight against cancer. Femtech World caught up with CEO and co-founder Oriana Papin-Zoghbi for our latest Insider Insight piece.
What is your morning routine?
I try to wake up before my toddler to enjoy a quiet morning with a cup of coffee, but most days, she’s an early riser, and we jump straight into breakfast. We have breakfast as a family, and then I take her to school—this quality time with her is one of my favorite parts of the day.
A few days a week, I make an effort to get up extra early to fit in a workout, which is essential for me. Once I’m back and ready to start my workday, I check my Notion dashboard to organize my tasks before diving into emails. This helps set me up for success and helps me prioritize tasks for the day.
Which technology could you not live without?
I couldn’t live without Notion, it’s like my second brain. I’m a strong believer in David Allen’s Getting Things Done method, a personal productivity approach that redefines how you manage both life and work. It emphasizes that when your mind is overloaded, you can’t think as clearly or effectively, so staying organized is key
How do you relax?
I’m still working on getting better at relaxing, but as someone who’s always striving to get things done, it can be a challenge. The best way for me to unwind is by taking walks with my family and our dog. We love strolling around the city and spending time at the park.
Which quote resonates with you?
If you can dream it, you can do it’ – Walt Disney. As an immigrant from a humble background, this quote deeply resonates with me. My family worked incredibly hard, dreamed big, and made it happen. It’s a philosophy I’ve always embraced.
What is the best thing about your job?
The best part of my job is the incredible people I work with and our shared mission to create a better future for ovarian cancer patients. This mission drives me every day. I feel truly fortunate to be on this journey with my co-founders, team, investors, advisors, and everyone helping us make early detection a reality.
What keeps you motivated?
Indignation on the status of women’s health, especially now that I have a daughter and have experienced my own challenging journey to start a family.
What is the most important lesson you have learned on your start-up journey?
The most important lesson I’ve learned on my startup journey is that hiring is everything. Bringing on the right people can make or break your company. I heard this advice early on, but it wasn’t until I experienced it firsthand that I truly understood how crucial it is.
What advice would you give to your younger self?
Work for people, not just companies. In the early stages of your career, it’s essential to soak up as much knowledge as possible, as traditional education only takes you so far. Seek out companies with strong leaders who can mentor you during these formative years. Instead of chasing the trendiest company, focus on finding the right people, great managers and colleagues, who will support your growth and development.
What is something you wish you could experience again for the first time?
My wedding. Throughout my life, I’ve moved around the world, and my husband has also experienced his share of relocations. Our friends and family are scattered across different corners of the globe, so our wedding was the one occasion when everyone came together in one place. I felt incredibly grateful to have all of them there to celebrate with us. It was one of the most special moments of my life, and I cherished being surrounded by the people I love most.
What is your greatest achievement since establishing AOA?
Building our team has been our greatest achievement and the most significant learning curve. While we’ve had success in raising capital, publishing papers, de-risking our technology, making progress on our milestones, etc, none of this would have been possible without our team.
My co-founders, Alex, Anna, and I have worked diligently to assemble a phenomenal group of individuals who are truly passionate and committed to AOA.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Wellness4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Hormonal health3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Hormonal health6 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health






